Key result
Study design compares D-dimer levels during chronic anticoagulation between DOACs and VKAs.
Why the study?
Comparisons of D-dimer levels between patients on VKAs versus DOACs, as well as between different DOACs, are scanty, potentially explaining discrepancies in D-dimer-guided extended anticoagulation.
Does the type of anticoagulation (DOACs vs VKAs) impact D-dimer levels during chronic therapy?
Observational
Does the type of anticoagulation (DOACs vs VKAs) impact D-dimer levels during chronic therapy?
Answers are grounded in this paper and cite their sources.
This study aims to determine if D-dimer levels differ between patients on VKAs versus DOACs, which may explain discrepancies in trials using D-dimer to guide extended anticoagulation.
D-dimer is often increased in patients with or at risk of venous thromboembolism (VTE) 1 and is decreased after starting anticoagulation. 2 Patients with D-dimer above cutoff after stopping anticoagulation are at risk of recurrent VTE.3,4 Accordingly, high D-dimer is employed as a biomarker to guide decisions on extended anticoagulation with vitamin K antagonists (VKAs).5,6 This concept was introduced by the Prolong prospective trial 5 that included patients with unprovoked VTE, who had been on VKAs for at least 3 months.D-dimer was measured 1 month after stopping anticoagulation.Patients with D-dimer below the cutoff mark stopped anticoagulation and those with D-dimer above cutoff were randomized to resume or stop anticoagulation.Patients were followed up for 1.5 years to record recurrent VTE.The analysis showed that patients with increased D-dimer who stopped VKAs, had increased rates of recurrent VTE when compared with patients resuming anticoagulation.Hence, the study concluded that patients presenting with D-dimer above cutoff after stopping VKAs are candidates for extended anticoagulation.5 Subsequent studies debated on whether D-dimer below cutoff can be taken as a biomarker to safely stop anticoagulation.7,8 Recently, a similar protocol (Apidulcis) 8 was applied to patients, who after unprovoked VTE and treatment with any anticoagulant for at least 12 months, underwent D-dimer measurement during anticoagulation.If D-dimer level was below the cutoff, measurements were performed 15, 30, and 60 days after stopping anticoagulation.Patients with D-dimer levels below cutoff stopped anticoagulation and patients with the first D-dimer levels above cutoff were offered apixaban dose (2.5 mg, twice daily).Patients were followed up to 18 months to record recurrent VTE.7 The proportion of patients on direct oral anticoagulants (DOACs) included in the study was 91.3%.The study was prematurely interrupted because of excess primary outcomes in patients with D-dimer below cutoff who stopped anticoagulation.Hence, at variance with the Prolong, Apidulcis did not confirm the value of D-dimer measurement to stratify patients for extended anticoagulation.8 A reason that may account for the discrepancy could be the fact that Apidulcis was conducted during the COVID-19 pandemic.Hence, patients included in the study might have had increased VTE risk because of lockdown that limited physical activity.9 Herein, we propose another possible explanation.It could be that the type of anticoagulation (VKAs vs DOACs) may impact differently on D-dimer levels achieved during anticoagulation.Comparisons of D-dimer levels for patients on VKAs vs those on DOACs are scanty.Furthermore, there is little information on comparisons of D-dimer for patients taking different DOACs.Finally, most studies investigated D-dimer for patients on DOACs either at peak or trough.With this background, we undertook investigations aimed at comparing D-dimer during chronic anticoagulation for patients on VKAs vs DOACs.D-dimer for patients on DOACs was tested at peak and trough.The study was approved by the local ethics committee and all patients gave informed consent.
No takes yet. Share an insight, caveat, or question.
Tripodi et al. (2024) conducted an observational in Venous thromboembolism (VTE) on chronic anticoagulation. DOACs vs. VKAs was evaluated on D-dimer levels during chronic anticoagulation. The abstract describes the rationale and design of a study comparing D-dimer levels during chronic anticoagulation in patients taking VKAs versus DOACs, but reports no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: